First and only PARP inhibitor to improve invasive disease-free survival in patients
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
In clinical trials, treatment proved more effective than other therapies evaluated
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Food-tech disruptor prepares to vastly scale dairy-identical, non-animal milk protein production in a pioneering sustainable industrial park in Denmark
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Routine tests undertaken by women dropped by 35% in 2020
Women's health is in fact a direct reflection of the nation's overall health
Subscribe To Our Newsletter & Stay Updated
